ziftomenib
An orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, with potential antineoplastic activity. Upon oral administration, ziftomenib prevents the interaction between the two proteins menin and MLL, and thus the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth and proliferation of certain kinds of leukemia cells.
| Synonym: | menin-KMT2A inhibitor KO 539 menin-mixed lineage leukemia protein-protein interaction inhibitor KO 539 menin-MLL inhibitor KO-539 menin-MLL interaction inhibitor KO 539 |
|---|---|
| Code name: | KO 539 KO-539 KO539 |